NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: The Company operates in three segments: Nature's Sunshine Products (United States and International) and Synergy Worldwide. It markets health and wellness products through a direct sales force of independent Distributors and Managers.

Key Financial Metrics

Amounts in thousands, except per-share data.

Margins (Six Months 2005):
- Gross Margin (Net Sales less COGS): ~82.9%
- Operating Margin: 5.9%
- Net Profit Margin: 4.6%

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8.1% for the quarter and 9.6% for the six-month period compared to the prior year, driven by volume increases in International, Synergy Worldwide, and U.S. operations.
• Profitability:
  • Quarterly: Net income decreased 15.6% to $4.07 million (from $4.82 million) primarily due to a higher effective tax rate (12.6% vs. a benefit in the prior year) and increased volume incentives.
  • Six-Month: Net income increased 2.9% to $8.03 million (from $7.81 million) as operating income grew 23.2%.
• Expense Trends: Volume incentives increased to 40.4% of sales (quarter) and 39.6% (six months) compared to 37.4% and 37.7% in the prior year, attributed to the mix of sales from Synergy Worldwide which carries higher incentive rates.
• Segment Performance:
  • International: Sales up 22.4% (quarter) and 17.1% (six months), with strong performance in Russia, Japan, Canada, and Colombia.
  • Synergy Worldwide: Reported an operating loss of $1.1 million for the quarter and $0.7 million for the six months, compared to operating income in the prior year, due to costs associated with launching distribution operations in Japan.

Guidance, Outlook, and Risks

• Outlook: Management expects cost of goods sold to increase slightly as a percent of sales for the remainder of 2005. Volume incentives are expected to remain relatively constant. SG&A expenses as a percent of sales are expected to decrease due to cost controls and sales growth. The effective tax rate is expected to increase slightly for the balance of the year.
• Capital Allocation: On August 5, 2005, the Company commenced a Dutch auction tender offer for up to 500,000 shares at a price between $21.00 and $22.25, expected to cost approximately $11.3 million. The Company intends to pay off its $5 million line of credit during 2005.
• Risks and Contingencies:
  • Product Liability: The Company self-insures for product liability and cannot obtain insurance for products containing ephedrine alkaloids and kava due to regulatory scrutiny. While reserves are accrued, actual liabilities could exceed estimates.
  • Foreign Currency: Approximately 57.4% of revenue is realized outside the U.S. A strengthening U.S. dollar negatively impacts operating results. The Company does not use derivative instruments for hedging.
  • Accounting Changes: The Company is evaluating the adoption of SFAS No. 123R (Share-Based Payment), which will require recognizing stock option costs as expense, though management does not believe the impact will be material.

Investor Verification Checklist

• Verify the sustainability of the 22.4% sales growth in the International segment and the timeline for Synergy Worldwide to return to profitability.
• Review the adequacy of self-insurance reserves for product liability claims, particularly regarding kava and ephedra-related litigation.
• Monitor the impact of the new SFAS No. 123R accounting standard on future net income and EPS.
• Assess the execution of the Dutch auction tender offer and its impact on cash reserves and share count.
• Track the effective tax rate for the remainder of 2005 to confirm management's expectation of a slight increase.